Evidence has shown that certain conditions, characterized by high baseline retrotransposon expression and dsRNA levels with optional IFN activation, can prime cancers for viral mimicry induction and anti-tumor activity upon treatment with epigenetic therapy (“viral mimicry priming”) [29, 35]. This evidence concerns the gene IFNA1 and neoplasm.